###### Strengths and limitations of this study

-   This is the first study to evaluate light microscopy criteria to diagnose urogenital gonorrhoea in Indonesia.

-   This is a multicentre study conducted in several participating clinics in three major cities in Indonesia.

-   The technical fluency among clinicians and laboratory technicians working in clinic-based settings may differ from those working in outreach settings and influence the outcome, but this was not evaluated in our study.

-   The clinical workload in the participating clinics was not prospectively measured but estimated in a post hoc analysis.

Introduction {#s1}
============

Gonorrhoea, caused by *Neisseria gonorrhoeae* (Ng), is the second most common bacterial sexually transmitted infections (STIs) worldwide.[@R1] The variety of diagnostic methods used in different settings and regions may influence the observed epidemiological patterns of gonorrhoea.[@R1]

Nowadays, nucleic acid amplification tests (NAATs) are considered the standard to diagnose gonorrhoea, both for male and female patients.[@R3] However, NAAT is not always available due to high prices, the required infrastructure and the need for qualified personnel.[@R4] As a result, a diagnostic method based on clinical symptoms and signs (syndromic approach) and/or light microscopic findings is currently the standard in many resource-limited countries, such as Indonesia.[@R5] Furthermore, resources are also scarce in an outreach setting, a form of service used frequently to reach target groups who are at risk of STI but have poorer access to institutionalised health centres, for example, sex workers, men who have sex with men (MSM) and transwomen.[@R7]

Syndromic approach is considered to be sensitive and specific in symptomatic males.[@R5] Yet, this approach has been increasingly criticised because of its poor performance in diagnosing gonorrhoea among females and asymptomatic individuals.[@R8] As a consequence, antibiotics are both overused and underutilised, and this fuels antimicrobial resistance and spread of infections because of underdiagnosis.[@R8]

Thus, in addition to syndromic approach, light microscopic examination of Gram-stained smears to support a urogenital gonorrhoea diagnosis is recommended.[@R2] Two light microscopic findings are used as a criterion for urogenital gonorrhoea: an elevated number of polymorphonuclear leucocytes (PMNLs) and the presence of intracellular Gram-negative diplococci (IGND).[@R2]

Since the widespread introduction of NAAT to screen for gonorrhoea is too costly and therefore not realistic in many resources-limited settings, we evaluated the performance of these two light microscopic criteria to diagnose urethral and endocervical gonorrhoea in clinic-based and outreach settings in three major cities in Indonesia: Jakarta, Yogyakarta and Denpasar, and compared them with detection of Ng with a PCR test (Ng-PCR) performed at the Public Health Laboratory of Amsterdam, the Netherlands.

Material and methods {#s2}
====================

This study was approved by the Medical and Health Research Ethics Committee (MHREC), Faculty of Medicine Universitas Gadjah Mada (\#KE/FK/38/EC).

Study population {#s2a}
----------------

Between January and December 2014, two clinic-based and six outreach STI service facilities in Jakarta, Yogyakarta and Denpasar, Indonesia, recruited participants for the investigation of the epidemiology of urogenital gonorrhoea.[@R13] The length of the recruitment period varied per clinic (from 1 month to 5 months). All accessible males, females and transwomen (who had not undergone genital reconstructive surgery) clients, who were aged 16 years or older at the day of inclusion and who provided written informed consent were consecutively screened regardless of other demographics and clinical characteristics.

The original aim of the study was to estimate prevalence of gonorrhoea among STI clinic clients in Indonesia and to assess the antibiotic susceptibility patterns of *N. gonorrhoeae* strains found in these clients. The current study is a post hoc, exploratory analysis, and no formal sample size calculation was performed.

Data collection {#s2b}
---------------

In the clinic-based setting, participants visited the clinics during regular service hours (daytime: 09:00--15:00; evening: 15:00--21:00), whereas in the outreach setting, healthcare providers visited the outreach venues, for example, community gatherings, saunas and massage parlours, not necessarily during regular service hours.

We used a paper-based self-administered questionnaire to assess participants' demographics, sexual history and clinical characteristics. In case of illiteracy or on request of the participant, a healthcare worker or counsellor assisted in completing the questionnaire. In the outreach setting, several participants might complete the questionnaire at the same moment.

Symptomatic participants were defined as those who reported the presence of genital discharge and/or pain at the day of consultation.

In both settings, samples were examined on site. A clinician collected one urogenital sample per participant (from the urethra of males and transwomen, or the endocervix of females) using an ESwab (Copan Italia S.P.A., Brescia, Italy)[@R14] and produced the smear. A laboratory technician (with a minimum education in medical laboratory or biomedical science, and a training in performing light microscopy according to Indonesian national STI guideline,[@R6]) performed Gram staining and examined the samples by light microscopy. The first light microscopic criterion was the PMNLs count. The cut-off value for a positive result was prespecified according to the guideline as ≥5 PMNL/oil-immersion field (oif) for urethral samples and ≥20 PMNL/oif for endocervical samples.[@R6] The second light microscopic criterion was the presence of IGND.[@R6]

From all participating clinics, collected urogenital samples were transferred in ESwab medium (Copan Italia S.P.A.) to the Research Laboratory Facility (Fasilitas Penelitian Bersama-FALITMA), Faculty of Biology Universitas Gadjah Mada in Yogyakarta, Indonesia, and stored at −80°C before they were transferred on dry ice to the reference laboratory at Public Health Service (GGD) of Amsterdam, the Netherlands, for Ng*-*PCR.[@R14] At the reference laboratory, DNA was extracted from the samples by isopropanol precipitation. Presence of Ng was tested by detecting *opa* genes in the validated Ng-PCR, as described.[@R15] The procedure was performed in the Rotorgene system (Qiagen N.V, Venlo, the Netherlands) using protocol, primers and probes, as described.[@R16] Sensitivity and specificity of the PCR method in an earlier study were 95% and 99%, respectively.[@R15] Performers of PCR were blinded for the results of light microscopy. The use of Indonesian national guideline for the management for STI for light microscopy[@R6] and the protocol of the reference laboratory for the PCR ensured that all participants had complete and conclusive laboratory data for the analysis. A subset of samples that were IGND positive but were negative in Ng-PCR was sent to the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, for investigation of the presence of *Neisseria meningitidis*, as described.[@R17]

In addition, data on daily number of inclusions, number of samples examined and number and job description of staff involved in the study were collected from participating clinics as part of study administration.

Statistical analysis {#s2c}
--------------------

Statistical analysis was performed in STATA V.13. Demographics, sexual history and clinical characteristics of the participants were described, overall and by service setting.

Separate analyses of diagnostic accuracy were performed for urethral (from male and transwomen) and endocervical samples. Diagnostic accuracy of the two light microscopy criteria compared with the reference test, Ng-PCR, was assessed by calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and their 95% CI using two-by-two contingency tables, and also by calculating Cohen\'s kappa coefficient and its SE.[@R18] We performed exploratory analyses to examine the differences in sensitivity and specificity by microscopy criteria (using McNemar\'s test) and by service settings and symptomatology (using χ^2^ test).

We performed a post hoc analysis to describe participating clinic\'s performance. We described number and job description of staff involved in the study. Clinic\'s workload was described as the number of samples examined per hour based on daily number of inclusions, number of samples examined and time spent for sample analysis (estimated).

Results {#s3}
=======

Characteristics of participants and participating clinics {#s3a}
---------------------------------------------------------

In total, data of 992 participants were examined: 632 males (including 97 transwomen) ([table 1](#T1){ref-type="table"}, [supplementary figures 1--3](#SP1){ref-type="supplementary-material"}) and 360 females ([table 2](#T2){ref-type="table"}, online [supplementary figures 4--6](#SP1){ref-type="supplementary-material"}). Part of the study population and their characteristics were included in an earlier report.[@R13] Of the males, 47.6% were recruited in clinic-based and 52.4% in outreach settings, 53.6% were MSM and 17.3% had symptoms. Of the females, 92.2% were recruited in outreach settings, 86.4% were sex workers and 28.1% had symptoms.
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###### 

Demographics and clinical characteristics of 632 male/transwoman participants recruited in Jakarta, Yogyakarta and Denpasar (January--December 2014)

  Variables                                                        All (n=632)   Clinic based (n=301)   Outreach (n=331)   p Values¶
  ---------------------------------------------------------------- ------------- ---------------------- ------------------ -------------
  City of recruitment                                                                                                      **\<0.001**
   Jakarta                                                         153 (24.2)    0 (0.0)                153 (46.2)         
   Yogyakarta                                                      221 (35.0)    43 (14.3)              178 (53.8)         
   Denpasar                                                        258 (40.8)    258 (85.7)             0 (0.0)            
  Median age (IQR)\*, in years                                     27 (24--33)   27 (24--32)            27 (23--35)        0.64
  Age group                                                                                                                **\<0.001**
   16--24 years                                                    201 (31.8)    82 (27.2)              119 (35.9)         
   25--34 years                                                    290 (45.9)    165 (54.8)             125 (37.8)         
   ≥35 years                                                       141 (22.3)    54 (17.9)              87 (26.3)          
  Risk group                                                                                                               **\<0.001**
   Male sex workers                                                167 (26.4)    62 (20.6)              105 (31.7)         
   Men who have sex with men                                       339 (53.6)    210 (69.8)             129 (39.0)         
   Transwomen\*                                                    97 (15.4)     3 (1.0)                94 (28.4)          
   Heterosexuals who are not sex workers                           29 (4.6)      26 (8.6)               3 (0.9)            
  Being notified of possibility contracting STI from partner(s)†                                                           **\<0.001**
   No                                                              463 (73.3)    256 (85.1)             207 (62.5)         
   Yes                                                             169 (26.7)    45 (14.9)              124 (37.5)         
  Time between last sex contact and the day of consultation                                                                **\<0.001**
   0 days                                                          45 (7.1)      14 (4.7)               31 (9.4)           
   1--3 days                                                       208 (32.9)    54 (17.9)              154 (46.5)         
   4--7 days                                                       114 (18.0)    55 (18.3)              59 (17.8)          
   \>7 days                                                        265 (41.9)    178 (59.1)             87 (26.3)          
  Urogenital symptoms‡                                                                                                     **0.001**
   No                                                              523 (82.8)    233 (77.4)             290 (87.6)         
   Yes                                                             109 (17.3)    68 (22.6)              41 (12.4)          
  Reported history of STI§                                                                                                 0.37
   No                                                              414 (65.5)    192 (63.8)             222 (67.1)         
   Yes                                                             136 (21.5)    72 (23.9)              64 (19.3)          
   Unsure                                                          82 (13.0)     37 (12.3)              45 (13.6)          
  Reported past antibiotics use§                                                                                           0.11
   No                                                              423 (66.9)    200 (66.5)             223 (67.4)         
   Yes                                                             139 (22.0)    60 (19.9)              79 (23.9)          
   Unsure                                                          70 (11.1)     41 (13.6)              29 (8.8)           

\*Median value with IQR.

†In the preceding 3 months, including the day of consultation.

‡Reported genital discharge and/or genital pain at the day of consultation.

§In the preceding 3 months, not including the day of consultation.

¶p Values calculated using χ^2^ test for categorical variables or Kruskal-Wallis test for continuous variables.

STI, sexually transmitted infection.

###### 

Demographics and clinical characteristics of 360 female participants recruited in Jakarta and Yogyakarta (January--December 2014)

  Variables                                                        All (n=360)     Clinic based (n=28)   Outreach (n=332)   p Values¶
  ---------------------------------------------------------------- --------------- --------------------- ------------------ -------------
  City of recruitment                                                                                                       **\<0.001**
   Jakarta                                                         232 (64.4)      0 (0.0)               232 (69.9)         
   Yogyakarta                                                      128 (35.6)      28 (100.0)            100 (30.1)         
  Median age (IQR)\*, in years                                     30 (24--36.5)   29 (24--37.5)         30 (24--36)        0.05
  Age group                                                                                                                 0.55
   16--24 years                                                    102 (28.3)      8 (28.6)              94 (28.3)          
   25--34 years                                                    146 (40.6)      9 (32.1)              137 (41.3)         
   ≥35 years                                                       112 (31.1)      11 (39.3)             101 (30.4)         
  Risk group                                                                                                                
   Female sex workers                                              311 (86.4)      3 (10.7)              308 (92.8)         **\<0.001**
   Heterosexuals who are not sex workers                           49 (13.6)       25 (89.3)             24 (7.2)           
  Being notified of possibility contracting STI from partner(s)†                                                            **0.009**
   No                                                              274 (76.1)      27 (96.4)             247 (74.4)         
   Yes                                                             86 (23.9)       1 (3.6)               85 (25.6)          
  Time between last sex contact and the day of consultation                                                                 **\<0.001**
   0 days                                                          49 (13.6)       0 (0.0)               49 (14.8)          
   1--3 days                                                       240 (66.7)      9 (32.1)              231 (69.6)         
   4--7 days                                                       38 (10.6)       11 (39.3)             27 (8.1)           
   \>7 days                                                        33 (9.2)        8 (28.6)              25 (7.5)           
  Urogenital symptoms‡                                                                                                      **\<0.001**
   No                                                              259 (71.9)      11 (39.3)             258 (74.7)         
   Yes                                                             101 (28.1)      17 (60.7)             84 (25.3)          
  Reported history of STI§                                                                                                  0.72
   No                                                              297 (82.5)      24 (85.7)             273 (82.2)         
   Yes                                                             42 (11.7)       2 (7.1)               40 (12.1)          
   Unsure                                                          21 (5.8)        2 (7.1)               19 (5.7)           
  Reported past antibiotics use§                                                                                            **0.002**
   No                                                              146 (40.6)      20 (71.4)             126 (37.9)         
   Yes                                                             171 (47.5)      6 (21.4)              165 (49.7)         
   Unsure                                                          43 (11.9)       2 (7.1)               41 (12.4)          

\*Median value with IQR.

†In the preceding 3 months, including the day of consultation.

‡Reported genital discharge and/or genital pain at the day of consultation.

§In the preceding 3 months, not including the day of consultation.

¶p Values calculated using χ^2^ test for categorical variables or Kruskal-Wallis test for continuous variables.

STI, sexually transmitted infection.

Among participants visiting clinic-based settings, the proportion of those who were symptomatic was higher (22.6% and 60.7%, respectively, for males and females) than among participants who were seen in the outreach settings (12.4% and 25.3%). Participants seen in the outreach setting were more often notified by a partner (37.5% and 25.6%, respectively, for males and females) than participants seen in the clinic-based settings (14.9% and 3.6%). In addition, most of male (55.9%) and female participants (84.4%) in the outreach settings reported sexual activity in the 3 days preceding the day of consultation, while this was only 22.6% and 32.1% respectively of those visiting the clinic-based settings.

In the post hoc estimation, total sample analysis time spent in clinic-based and outreach settings during the study period was estimated to be 512 and 276 hours, respectively, and the workload was estimated to be 0.54 and 2.40 samples per hour, respectively (see [table 3](#T3){ref-type="table"}).

###### 

Clinical workload in the participating clinics during participants recruitment period in Jakarta, Yogyakarta and Denpasar, Indonesia (January--December 2014)

  Participating clinics   City         Staff (number)                                                                 Recruitment period             Total inclusion days\*   Sample analysis time†   Number of samples   Workload per hour‡
  ----------------------- ------------ ------------------------------------------------------------------------------ ------------------------------ ------------------------ ----------------------- ------------------- --------------------
  Clinic-based settings                                                                                                                                                                                                   
   Clinic A               Yogyakarta   Dermatologist in training (2), nurse (1), lab technician (1), assistant§ (1)   January--Apr and July 2014     34                       204                     71                  0.35
   Clinic B               Denpasar     GP¶ (2), nurse (2), lab technician (1), counsellor (1)                         June--November 2014            68                       408                     258                 0.63
   Subtotal                                                                                                                                          102                      612                     329                 0.54
  Outreach settings                                                                                                                                                                                                       
   Clinic C               Jakarta      GP¶ (2), nurses (2), lab technician (1), assistant§ (1), counsellor (1--2)     March--May, and October 2014   9                        54                      233                 4.31
   Clinic D               Jakarta      GP¶ (2), lab technician (1), assistant§ (1), counsellor (1--2)                 March--May 2014                10                       60                      152                 2.53
   Clinic E               Yogyakarta   GP¶ (2), lab technician (1), assistant§ (1--2), counsellor (1---2)             April--July 2014               7                        42                      68                  1.62
   Clinic F               Yogyakarta   GP¶ (2), nurse (2), lab technician (1), assistant§ (1-2), counsellor (1-2)     March--June 2014               10                       60                      100                 1.67
   Clinic G               Yogyakarta   GP¶ (2), nurse (2), lab technician (1), assistant§ (1--2), counsellor (1--2)   April--June 2014               7                        42                      85                  2.02
   Clinic H               Yogyakarta   GP¶ (2), lab technician (1), assistant§ (1--2), counsellor (1--2)              April 2014                     3                        18                      25                  1.39
   Subtotal                                                                                                                                          46                       276                     663                 2.40

\*Inclusion day is defined as the day when participating clinic recruited participants for the study (post hoc calculation).

†Sample analysis time is defined as total duration (in hours) of time spent in the participating clinics for analysing participants' sample, estimated to be 6 hours/inclusion day regardless service setting (post hoc estimation).

‡Workload per hour is defined as average number of samples analysed per hour.

§Medical student trained in questionnaire administration of this study.

¶General practitioner trained in sexual health.

GP, general practitioner.

Diagnostic accuracy of light microscopy results compared with Ng-PCR {#s3b}
--------------------------------------------------------------------

The prevalence of urogenital gonorrhoea based on Ng-PCR in this study population was 21.2% in males/transwomen ([table 4](#T4){ref-type="table"}) and 28.9% in women ([table 5](#T5){ref-type="table"}). The prevalence in males/transwomen was 16.6% and 25.4%, respectively, for the clinic-based setting and for the outreach setting (χ^2^ test, p\<0.01). In women, this was 42.9% and 27.7% (χ^2^ test, p=0.09).

###### 

Accuracy of light microscopic criteria and syndromic approach to diagnose urogenital gonorrhoea in 632 males/transwomen in Jakarta, Yogyakarta and Denpasar, Indonesia (January--December 2014)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis criterion         N     Diagnosis outcome   Sensitivity   Specificity   PPV   NPV                   Kappa±\                                                                               
                                                                                                                SE                                                                                    
  --------------------------- ----- ------------------- ------------- ------------- ----- --------------------- --------- --------------------- --------- --------------------- --------------------- ------------
  1\. PMNL                                                                                                                                                                                            

  Overall                     632   79                  55            81            417   59.0 (50.1 to 67.4)   --        83.7 (80.2 to 86.9)   --        49.4 (41.4 to 57.4)   88.4 (85.1 to 91.1)   0.40±0.04

  Service settings                                                                                              0.018                           \<0.001                                               

   Clinic based               301   36                  14            21            230   72.0 (57.5 to 83.8)             91.6 (87.5 to 94.8)             63.2 (49.3 to 75.6)   94.3 (90.6 to 96.8)   0.60±0.05

   Outreach                   331   43                  41            60            187   51.2 (40.0 to 62.3)             75.7 (69.9 to 80.9)             41.8 (32.1 to 51.9)   82.0 (76.4 to 86.8)   0.25±0.05

  Urogenital symptoms\*                                                                                         0.07                            \<0.001                                               

   Absent                     523   59                  48            50            366   55.1 (45.2 to 64.8)             88.0 (84.5 to 91.0)             54.1 (44.3 to 63.7)   88.4 (84.9 to 91.3)   0.42±0.04

   Present                    109   20                  7             31            51    74.1 (53.7 to 88.9)             62.2 (50.8 to 72.7)             39.2 (25.8 to 53.9)   87.9 (76.7 to 95.0)   0.28±0.09

  2\. IGND                                                                                                                                                                                            

  Overall                     632   79                  55            53            445   59.0 (50.1 to 67.4    --        89.4 (86.3 to 91.9)   \-        59.9 (51.0 to 68.3)   89.0 (85.9 to 91.6)   0.49±0.04

  Service settings                                                                                              0.018                           \<0.001                                               

   Clinic based               301   36                  14            12            239   72.0 (57.5 to 83.8              95.2 (91.8 to 97.5)             75.0 (60.4 to 86.4)   94.5 (90.9 to 96.9)   0.68±0.06

   Outreach                   331   43                  41            41            206   51.2 (40.0 to 62.3              83.4 (78.2 to 87.8)             51.2 (40.0 to 62.3)   83.4 (78.2 to 87.8)   0.35±0.06

  Urogenital symptoms\*                                                                                         0.07                            \<0.001                                               

   Absent                     523   59                  48            30            386   55.1 (45.2 to 64.8              92.8 (89.9 to 95.1)             66.3 (55.5 to 76.0)   88.9 (85.6 to 91.7)   0.51±0.04

   Present                    109   20                  7             23            59    74.1 (53.7 to 88.9              72.0 (60.9 to 81.3)             46.5 (31.2 to 62.4)   89.4 (79.4 to 95.6)   0.38±0.09

  3\. Urogenital symptoms\*                                                                                                                                                                           

  Overall                     632   27                  107           82            416   20.2 (13.7 to 28.0)   --        83.5 (80.0--86.7)     --        24.8 (18.0 to 34.0)   79.5 (79.5 to 82.9)   0.04±0.04

  Service settings                                                                                              \<0.001                         0.06                                                  

   Clinic-based               301   19                  31            49            202   38.0 (24.7 to 52.8)             80.5 (75.0 to 85.2)             27.9 (17.7 to 40.2)   86.7 (81.7 to 90.8)   0.16±0.06

   Outreach                   331   8                   76            33            214   9.5 (4.2 to 17.9)               86.6 (81.8 to 90.6)             19.5 (8.8 to 34.9)    73.8 (68.3 to 78.8)   −0.05±0.05
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Reported genital discharge and/or genital pain at the day of consultation.

IGND, intracellular Gram-negative diplococcus; Ng-PCR, *Neisseria gonorrhoeae* PCR; NPV, negative predictive value; p, p values calculated using χ^2^ test; PMNL, polymorphonuclear leucocytes; PPV, positive predictive value.

###### 

Accuracy of light microscopic criteria and syndromic approach to diagnose urogenital gonorrhoea in 360 females in Jakarta and Yogyakarta, Indonesia (January--December 2014)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnostic criterion        N     Diagnosis outcome   Sensitivity   Specificity   PPV   NPV                   Kappa±\                                                                                
                                                                                                                SE                                                                                     
  --------------------------- ----- ------------------- ------------- ------------- ----- --------------------- --------- --------------------- --------- ---------------------- --------------------- ------------
  1\. PMNL                                                                                                                                                                                             

  Overall                     360   33                  71            82            174   31.7 (23.0 to 41.6)   --        68.0 (61.9 to 73.6)   --        28.7 (20.7-- to 7.9)   71.0 (64.9 to 76.6)   0.00±0.05

  Service settings                                                                                              0.23                            0.53                                                   

   Clinic based               28    2                   10            4             12    16.7 (2.1 to 48.4)              75.0 (47.6 to 92.7)             33.3 (4.3 to 77.7)     54.6 (32.2 to 75.6)   −0.09±0.17

   Outreach                   332   31                  61            78            162   33.7 (24.2 to 44.3)             67.5 (61.2 to 73.4              28.4 (20.2 to 37.9)    72.7 (66.3 to 78.4)   0.01±0.05

  Urogenital symptoms\*                                                                                         0.004                           \<0.001                                                

   Absent                     259   15                  53            48            143   22.1 (12.9 to 33.8)             74.9 (68.1 to 80.9)             23.8 (14.0 to 36.2)    73.0 (66.2 to 79.0)   −0.03±0.06

   Present                    101   18                  18            34            31    50.0 (32.9 to 67.1)             47.7 (35.2 to 60.5)             34.6 (22.0 to 49.1)    63.3 (48.3 to 76.6)   −0.02±0.09

  2\. IGND                                                                                                                                                                                             

  Overall                     360   33                  71            39            217   31.7 (23.0 to 41.6)   --        84.8 (79.8 to 88.9)   --        45.8 (34.0 to 58.0)    75.4 (70.0 to 80.2)   0.18±0.05

  Service settings                                                                                              0.23                            0.75                                                   

   Clinic based               28    2                   10            2             14    16.7 (2.1 to 48.4)              87.5 (61.7 to 98.5)             50.0 (6.8 to 93.2)     58.3 (36.6 to 77.9)   0.05±0.15

   Outreach                   332   31                  61            37            203   33.7 (24.2 to 44.3)             84.6 (79.4 to 88.9)             45.6 (33.5 to 58.1)    76.9 (71.3 to 81.8)   0.20±0.05

  Urogenital symptoms\*                                                                                         0.004                           0.005                                                  

   Absent                     259   15                  53            22            169   22.1 (12.9 to 33.8)             88.5 (83.1 to 92.6)             40.5 (24.8 to 57.9)    76.1 (70.0 to 81.6)   0.13±0.06

   Present                    101   18                  18            17            48    50.0 (32.9 to 67.1)             73.9 (61.5 to 84.0)             51.4 (34.0 to 68.6)    72.7 (60.4 to 83.0)   0.24±0.10

  3\. Urogenital symptoms\*                                                                                                                                                                            

  Overall                     360   36                  68            65            191   34.6 (25.6 to 44.6)   --        74.6 (68.8 to 79.8)   --        35.6 (26.4 to 45.8)    73.8 (67.9 to 79.0)   0.09±0.05

  Service settings                                                                                              \<0.001                         0.08                                                   

   Clinic based               28    10                  2             7             9     83.3 (51.6 to 97.9)             56.3 (29.9 to 80.3)             58.8 (32.9 to 81.6)    81.8 (48.2 to 97.7)   0.38±0.18

   Outreach                   332   26                  66            58            182   28.3 (19.4 to 38.6)             75.8 (69.9 to 81.1)             31.0 (21.3 to 42.0)    73.4 (67.4 to 78.8)   0.04±0.05
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Reported genital discharge and/or genital pain at the day of consultation.

IGND, intracellular Gram-negative diplococcus; Ng-PCR, *Neisseria gonorrhoeae* PCR; NPV, negative predictive value; p, p values calculated using χ^2^ test; PMNL, polymorphonuclear leucocytes; PPV, positive predictive value.

For urethral infections in males/transwomen, sensitivity (95% CI), specificity (95% CI) and kappa±SE of PMNL were 59.0% (50.1 to 67.4), 83.7% (80.2--86.9) and 0.40±0.04 and of IGND were 59.0% (50.1 to 67.4), 89.4% (86.3 to 91.9) and 0.49±0.04, respectively ([table 4](#T4){ref-type="table"}). IGND and PMNL differed significantly in specificity (χ^2^ test, p\<0.001). Using IGND as diagnostic criterion for urethral gonorrhoea, clinic-based settings performed better (72.0% (57.5 to 83.8), 95.2% (91.8 to 97.5) and 0.68±0.06) than outreach settings (51.2% (40.0 to 62.3), 83.4% (78.2 to 87.8) and 0.35±0.06).

We also observed a better performance in clinic-based settings compared with outreach settings when PMNL was used as the diagnostic criterion. Both IGND and PMNL gave better accuracy if compared with syndromic approach. Sensitivity, specificity and kappa±SE of syndromic approach for males/transwomen was 20.2% (13.7 to 28.0), 83.5% (80.0 to 86.7) and 0.04±0.04, respectively.

For endocervical infection in females, overall sensitivity, specificity and kappa*±*SE of PMNL were respectively 31.7% (23.0 to 41.6), 68.0% (61.9 to 73.6) and 0.00±0.05, respectively; of IGND, these were 31.7% (23.0 to 41.6), 84.8% (79.8 to 88.9) and 0.18±0.05, respectively ([table 5](#T5){ref-type="table"}). The difference in specificity between IGND and PMNL was significant (Χ^2^ test, p\<0.001). Performances of microscopy were not significantly different from syndromic approach.

For both urethral and endocervical samples, we observed that all samples that were positive for IGND were also positive for the PMNL criterion. In addition, out of 53 male urethral and 39 endocervical samples that were IGDN positive but Ng-PCR negative, none of the samples were positive for *N. meningitidis* DNA.

Discussion {#s4}
==========

Our study showed that light microscopic examination of Gram-stained urethral smears has some added value to diagnose gonorrhoea in males/transwomen, compared with the syndromic management based on signs and symptoms only. Furthermore, the IGND criterion in male urethral samples showed a better accuracy than PMNL, that is, a similar sensitivity, but higher specificity, PPV, NPV and kappa coefficient. Yet, for endocervical samples, light microscopy criteria have no added value over syndromic approach, as both the IGND and PMNL criteria performed poorly.

Overall, the accuracy of light microscopy for male urethral and endocervical samples in our study was poorer than those reported by previous studies.[@R12] This was possibly caused by different criteria used in defining the outcomes of microscopy and/or by different methods used as a reference test. We examined the accuracy of each criterion (PMNL and IGND) independently, while previous studies mostly combined these criteria to define the outcome of microscopy.

The presence of diplococcus (IGND) could be a strong indication for Ng infection.[@R2] However, a negative PCR result in an IGND-positive sample could result from misinterpretation in microscopy.[@R3] Various morphotypes other than Ng could also be found in urogenital samples and may resemble IGND, for example, other members of the *Neisseriaceae* family and *Moraxella catarrhalis*.[@R2] *N. meningitidis*, for example, is commensal to human oro-pharynx but has also been described as a pathogen in urethritis in males.[@R22] In this study, however, we could exclude urogenital tract colonisation by *N. meningitidis* as an explanation for the PCR-negative and IGND-positive cases.

In contrast, the presence of PMNL is an indication for inflammation that could be caused by a variety of microorganisms, including bacteria (eg, *Chlamydia trachomatis* and *Mycoplasma genitalium*), viruses and parasites and also by mechanical damage.[@R21] PMNLs are also observable in the female genital tract due to dysbiosis.[@R20] Thus, PMNL count is not an accurate parameter concerning specific cause of inflammation. Furthermore, 5% of urethral gonococcal infections diagnosed by NAAT showed no signs of inflammation (≥5 PMNL cells/oif).[@R25]

Since we observed that all IGND positive samples in our study were also positive for the PMNL criterion, it might be preferable to only use IGND as a diagnostic criterion for urogenital gonorrhoea and set aside the PMNL count. However, accuracy of both IGND and PMNL criteria may be reduced in case the male client has recently urinated.[@R21]

For diagnosing endocervical gonococcal infections, performing microscopy on endocervical samples has no additional value for the diagnosis of urogenital gonorrhoea since the sensitivity and the specificity of both microscopic criteria were poor, as described,[@R3] and were similar to that of syndromic management. In cervical and vaginal smears, it is possible to miss IGND due to a low load Ng infection, an abundance of PMNL, debris or high loads of other bacteria that predominate over IGND.[@R19]

To analyse urogenital smears for the presence of IGND, the Gram-staining procedure is the preferable method advised.[@R2] Other methods like methylene blue or crystal violet lack the required distinction of Gram-negative from Gram-positive diplococci and may be useful only for investigating urethral infection.[@R26] This implies that the accuracy of light microscopy may be influenced by instrumental factors (such as the quality of the staining chemicals and the condition of the microscope), as well as technical fluency of staff members and their compliance to the procedural standard in obtaining the samples, preparing and staining the smears and examining slides by microscopy.[@R2]

In addition, we observed that the accuracy of light microscopic examination for urethral samples was moderate in the clinic-based settings but was much poorer in the outreach settings. Individuals recruited in outreach settings of our study, males and transwomen particularly, were at relatively higher risk than those recruited in clinic-based settings; this is reflected in a higher positivity rate of urethral infections. Disease prevalence may influence performance of a diagnostic test, including predictive values and kappa.[@R18] For example, a population with a higher disease prevalence may include more severely diseased patients; therefore, the test performs better in this population.[@R27]

The variability of light microscopy accuracy may also be related to the clinical workload of the participating clinics.[@R7] Clinic-based settings had a much lower workload per hour compared with outreach settings. The length of time allocated for sample analysis may influence the compliance of the clinicians and the laboratory technicians to the procedure and thus affect the accuracy of the test. When the allocated time is limited, specificity decreases. Proportion of clients to healthcare workers is an important variable that influences the clinical workload.[@R7]

Here we show that the number of female clients (who were mostly sex workers) visiting outreach settings is by far higher than those in clinic-based settings. Outreach settings play a significant role in STI service delivery in Indonesia as they are preferred by members of key populations (including female sex workers), yield a high rate of case detection and are potentially more cost-effective.[@R7] Therefore, improving the quality of STI service in the outreach settings, including achieving a more rational clinical workload and maintaining the technical fluency of staff members, seems to be important.

In this study we also confirm that the use of syndromic approach for both male and female participants is not suitable to correctly diagnose a urogenital Ng infection, as reported.[@R8] However, evaluating symptoms might still be useful, as the accuracy of light microscopy is better (higher sensitivity and specificity) among symptomatic individuals. The presence of symptoms (genital discharge or pain), especially in males, possibly represents an actual and more severe type of gonococcal infection, in which PMNL and IGND are more likely to present under light microscopy examination of the smear.[@R8]

Limitations and strengths of the study {#s4a}
--------------------------------------

Our study has several limitations. We did not have any data regarding the numbers and characteristics of STI clients who were potentially eligible but refused to participate in the study. A good comparison of the accuracy of light microscopy in diagnosing endocervical infections between clinic-based and outreach setting was difficult because of the disproportion in the number of females recruited in the two settings. Most female participants, who were sex workers, were recruited in outreach settings. This was probably related to confidential, non-judgemental and free-of-charge STI services in the outreach settings, which were preferred by the members of key populations, including female sex workers.[@R29] Our study was conducted in a population with high gonorrhoea prevalence; this needs to be considered in generalising our findings to other settings. In addition, definition of accuracy level based on kappa is arbitrary and is subject to multiple interpretations.[@R18]

The technical fluency among clinicians and laboratory technicians working in clinic-based settings as opposed to outreach settings may differ and influence the outcome,[@R7] but this was not evaluated in our study. Furthermore, the clinical workload was not prospectively measured but estimated in a post hoc analysis.

Our study has also several strengths. This is the first study to evaluate light microscopy criteria to diagnose urogenital gonorrhoea in Indonesia. The study was performed in several participating clinics in three major cities in the country. In addition, to our knowledge, our observation regarding variability of the diagnostic accuracy by service setting has not been reported in earlier studies.

Conclusions {#s5}
===========

A moderate accuracy of IGND as a light microscopic criterion implies that it can be used as an option for diagnosing urethral gonorrhoea in males/transwomen in low resource settings. Based on its poor performance, using light microscopy for diagnosing endocervical infection should be discouraged. More advanced methods, such as NAAT, should be considered if financial resources are available, especially for endocervical infections, and to screen asymptomatic individuals.

Further studies are needed to determine whether the poor performance in the outreach settings was associated with clinical workload, instrumental and technical problems and/or environmental factors.
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